|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report on the identification of a putative self-binding β-zipper-forming peptide within the severe acute respiratory syndrome-associated coronavirus spike (S) protein and its application in viral detection.
|
29800727 |
2018 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Murine betacoronavirus (β-CoV) in group A uses the N-terminal domain (NTD) of S protein to bind to its receptor, whereas the β-CoVs severe acute respiratory syndrome CoV in group B and Middle East respiratory syndrome CoV in group C and several α-CoVs use the downstream C domain in their S proteins to recognize their receptor proteins.
|
26085157 |
2015 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model.
|
21592986 |
2011 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Many of these glycoproteins, including the severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) protein form trimeric units in the membrane of the native virion.
|
20168090 |
2010 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
First, different SARS-CoV sequences were analyzed to predict eight candidate peptides from conserved regions of the S protein based upon HLA-A*0201 binding and proteosomal cleavage.
|
19958537 |
2009 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV.
|
19198616 |
2009 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both the whole killed SARS-CoV vaccine (with and without alum) and adenovirus-based vectors encoding the nucleocapsid (N) and spike (S) protein induced neutralizing antibody responses and reduced viral replication and shedding in the upper respiratory tract and progression of virus to the lower respiratory tract.
|
18753223 |
2008 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, a paper was published in which it was proposed that the GxxxG motif of the severe acute respiratory syndrome (SARS) coronavirus spike (S) protein transmembrane domain plays a vital role in oligomerization of the protein (E. Arbely, Z. Granot, I. Kass, J. Orly, and I. T. Arkin, Biochemistry 45:11349-11356, 2006).
|
17507478 |
2007 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus.
|
16378996 |
2006 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the VSV-SARS-St19 is a useful tool for detecting Nabs against SARS-CoV.
|
17063504 |
2006 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The spike (S) protein is one of the best characterized proteins of SARS-CoV, which plays a key role in SARS-CoV overcoming species barrier and accomplishing interspecies transmission from animals to humans, suggesting that it may be the major target of selective pressure.
|
17020602 |
2006 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, this is the first report of small peptides designed to disrupt the binding of SARS-CoV S protein to ACE2.
|
16337697 |
2006 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Spike (S) protein is the most important membrane protein on the surface of severe acute respiratory syndrome coronavirus (SARS-CoV).
|
16289934 |
2006 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several live attenuated, genetically engineered or vector vaccines encoding the SARS-CoV spike (S) protein have been in pre-clinical studies.
|
16035944 |
2005 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previously, we have identified a truncated antigenic fragment named protein C [441 to 700 amino acids (a.a.)] as the immunodominant fragment of Spike (S) protein of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV).
|
15680149 |
2005 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The NL63 spike (S) protein mediated infection of different target cells compared with the closely related 229E-S protein but facilitated entry into cells known to be permissive to SARS-CoV-S-driven infection.
|
15897467 |
2005 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We constructed a recombinant adenovirus containing a truncated N-terminal fragment of the SARS-CoV Spike (S) gene (from--45 to 1469, designated Ad-S(N)), which encoded a truncated S protein (490 amino-acid residues, a part of 672 amino-acid S1 subunit), and investigated whether this construct could induce effective immunity against SARS-CoV in Wistar rats.
|
16022898 |
2005 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this report, the antiviral activity of 80R immunoglobulin G1 (IgG1), a human monoclonal antibody against severe acute respiratory syndrome coronavirus (SARS-CoV) spike (S) protein that acts as a viral entry inhibitor in vitro, was investigated in vivo in a mouse model.
|
15857975 |
2005 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two monoclonal antibodies (1A5 and 2C5) targeting at the RBD of S protein were isolated from mice immunized with inactivated SARS-CoV.
|
15749124 |
2005 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
By Western blotting, 97.5% of the SARS patients were positive for N protein-specific antibodies whereas only 47.5% of the samples were positive for S protein-specific antibodies.
|
15170626 |
2004 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recombinant SCoV S protein appears to be a suitable antigen for the development of an efficient and sensitive diagnostic test for SARS, but our data suggest that assay format and choice of S antigen are important considerations.
|
15195247 |
2004 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
We were able to pseudotype murine leukemia virus particles with S-protein and produce SARS pseudoviruses.
|
15262502 |
2004 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we showed that the S protein of SARS-CoV is highly immunogenic during infection and immunizations, and contains five linear immunodominant sites (sites I to V) as determined by Pepscan analysis with a set of synthetic peptides overlapping the entire S protein sequence against the convalescent sera from SARS patients and antisera from small animals immunized with inactivated SARS-CoV.
|
15356154 |
2004 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients.
|
15163706 |
2004 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
One scFv 80R efficiently neutralized SARS-CoV and inhibited syncytia formation between cells expressing the S protein and those expressing the SARS-CoV receptor angiotensin-converting enzyme 2 (ACE2).
|
14983044 |
2004 |